NO325598B1 - Anvendelse av PEG-IFN-<alfa>2A konjugat og ribavirin for fremstilling av et medikament for behandling av kronisk hepatitt C infeksjoner og PEG-IFN-<alfa>2A konjugater sammen med ribavirin for anvendelse i terapi. - Google Patents
Anvendelse av PEG-IFN-<alfa>2A konjugat og ribavirin for fremstilling av et medikament for behandling av kronisk hepatitt C infeksjoner og PEG-IFN-<alfa>2A konjugater sammen med ribavirin for anvendelse i terapi. Download PDFInfo
- Publication number
- NO325598B1 NO325598B1 NO20006178A NO20006178A NO325598B1 NO 325598 B1 NO325598 B1 NO 325598B1 NO 20006178 A NO20006178 A NO 20006178A NO 20006178 A NO20006178 A NO 20006178A NO 325598 B1 NO325598 B1 NO 325598B1
- Authority
- NO
- Norway
- Prior art keywords
- ifn
- ribavirin
- peg
- conjugate
- treatment
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims description 40
- 229960000329 ribavirin Drugs 0.000 title claims description 34
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 title claims description 15
- 239000003814 drug Substances 0.000 title claims description 8
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 title claims description 7
- 238000002560 therapeutic procedure Methods 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 108010047761 Interferon-alpha Proteins 0.000 description 8
- 102000006992 Interferon-alpha Human genes 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 229940047124 interferons Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 208000006154 Chronic hepatitis C Diseases 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000010710 hepatitis C virus infection Diseases 0.000 description 5
- 238000010606 normalization Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229950000038 interferon alfa Drugs 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 229940053146 rebetol Drugs 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010012770 Rebetron Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98110433 | 1998-06-08 | ||
| PCT/EP1999/003746 WO1999064016A1 (en) | 1998-06-08 | 1999-05-29 | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20006178L NO20006178L (no) | 2000-12-05 |
| NO20006178D0 NO20006178D0 (no) | 2000-12-05 |
| NO325598B1 true NO325598B1 (no) | 2008-06-23 |
Family
ID=8232086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006178A NO325598B1 (no) | 1998-06-08 | 2000-12-05 | Anvendelse av PEG-IFN-<alfa>2A konjugat og ribavirin for fremstilling av et medikament for behandling av kronisk hepatitt C infeksjoner og PEG-IFN-<alfa>2A konjugater sammen med ribavirin for anvendelse i terapi. |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20030053986A1 (ru) |
| EP (1) | EP1087778B1 (ru) |
| JP (2) | JP3839667B2 (ru) |
| KR (2) | KR20010052622A (ru) |
| CN (1) | CN1170543C (ru) |
| AR (1) | AR019855A1 (ru) |
| AT (1) | ATE307597T1 (ru) |
| AU (1) | AU767131B2 (ru) |
| BR (1) | BR9911076A (ru) |
| CA (1) | CA2334267C (ru) |
| CL (1) | CL2010000828A1 (ru) |
| CO (1) | CO5050297A1 (ru) |
| CZ (1) | CZ298681B6 (ru) |
| DE (1) | DE69927971T2 (ru) |
| DK (1) | DK1087778T3 (ru) |
| ES (1) | ES2251196T3 (ru) |
| HK (1) | HK1037981A1 (ru) |
| HR (1) | HRP20000808A2 (ru) |
| HU (1) | HU228218B1 (ru) |
| ID (1) | ID29285A (ru) |
| IL (2) | IL139786A0 (ru) |
| MA (1) | MA26641A1 (ru) |
| MY (1) | MY124091A (ru) |
| NO (1) | NO325598B1 (ru) |
| NZ (1) | NZ508249A (ru) |
| PE (1) | PE20000560A1 (ru) |
| PL (1) | PL192364B1 (ru) |
| RS (1) | RS50144B (ru) |
| RU (1) | RU2271217C2 (ru) |
| SA (1) | SA99200208B1 (ru) |
| SI (1) | SI1087778T1 (ru) |
| TR (1) | TR200003635T2 (ru) |
| TW (1) | TWI241913B (ru) |
| WO (1) | WO1999064016A1 (ru) |
| ZA (1) | ZA200006814B (ru) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010052622A (ko) * | 1998-06-08 | 2001-06-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CA2410579C (en) | 2000-05-26 | 2010-04-20 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses |
| ES2275711T3 (es) * | 2000-08-07 | 2007-06-16 | Sciclone Pharmaceuticals, Inc. | Tratamiento de la hepatitis c con timosina, interferon y ribavirina. |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
| CN101172993A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| JP2005533824A (ja) * | 2002-06-28 | 2005-11-10 | イデニクス（ケイマン）リミテツド | フラビウイルス科感染の治療のための２’−ｃ−メチル−３’−ｏ−ｌ−バリンエステルリボフラノシルシチジン |
| CN100348607C (zh) | 2002-06-28 | 2007-11-14 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒科病毒感染的2’和3’－核苷前药 |
| MXPA05005192A (es) * | 2002-11-15 | 2005-09-08 | Idenix Cayman Ltd | Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae. |
| PL377287A1 (pl) * | 2002-12-12 | 2006-01-23 | Idenix (Cayman) Limited | Sposób wytwarzania 2'-rozgałęzionych nukleozydów |
| AU2003300434A1 (en) * | 2002-12-23 | 2004-07-22 | Idenix (Cayman) Limited | Process for the production of 3'-nucleoside prodrugs |
| BRPI0419345B8 (pt) | 2003-05-30 | 2021-05-25 | Gilead Pharmasset Llc | uso do (2r)-2-desoxi-2-flúor-2-c-metil nucleosídeo e de uma composição farmacêutica que o compreende |
| US8615282B2 (en) | 2004-07-13 | 2013-12-24 | Dexcom, Inc. | Analyte sensor |
| BRPI0512360A (pt) * | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae |
| RU2433124C2 (ru) | 2004-09-14 | 2011-11-10 | Фармассет, Инк. | Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006281498A1 (en) * | 2005-08-15 | 2007-02-22 | F. Hoffmann-La Roche Ag | PEG-IFN alpha and ribavirin for HBV treatment |
| US9201979B2 (en) * | 2005-09-14 | 2015-12-01 | Millennial Media, Inc. | Syndication of a behavioral profile associated with an availability condition using a monetization platform |
| CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| WO2009156456A1 (en) | 2008-06-24 | 2009-12-30 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| AU2009293493B2 (en) * | 2008-09-17 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Combination of HCV NS3 protease inhibitor with interferon and ribavirin |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| SG172361A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside analogs |
| EP2376515A1 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| WO2010129947A2 (en) | 2009-05-08 | 2010-11-11 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as vaccine enhancers |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| KR20120099371A (ko) | 2009-08-05 | 2012-09-10 | 피어이스 에이지 | 리포칼린 뮤테인의 조절 방출 제형 |
| WO2011053617A1 (en) | 2009-10-30 | 2011-05-05 | Boehringer Ingelheim International Gmbh | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| PT3290428T (pt) | 2010-03-31 | 2021-12-27 | Gilead Pharmasset Llc | Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino |
| SG186161A1 (en) | 2010-06-08 | 2013-01-30 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
| CN103154023B (zh) | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | 铁调素的结合蛋白 |
| JP6100694B2 (ja) | 2010-11-15 | 2017-03-22 | ピエリス ファーマシューティカルズ ゲーエムベーハー | グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質 |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| EP2646552B1 (en) | 2010-12-02 | 2017-07-05 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for ctla-4 |
| ME03009B (me) | 2011-09-16 | 2018-10-20 | Gilead Pharmasset Llc | Metode za lecenje hcv-a |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN109432402B (zh) | 2011-12-13 | 2022-04-29 | 皮里斯制药有限公司 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140039923A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for receiving and managing patient data gathered during patient treatments |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EA029081B9 (ru) | 2013-01-31 | 2018-09-28 | Джилид Фармассет Ллс | Комбинированный состав двух противовирусных соединений |
| AU2014230460B2 (en) | 2013-03-14 | 2018-04-05 | Pieris Pharmaceuticals Gmbh | Novel binding proteins for PCSK9 |
| AU2014311827B2 (en) | 2013-08-27 | 2017-09-14 | Gilead Sciences, Inc. | Combination formulation of two antiviral compounds |
| EP3094650A2 (en) | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RU2723034C2 (ru) | 2014-05-22 | 2020-06-08 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые полипептиды со специфическим связыванием и пути их применения |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| EP4177262A1 (en) | 2015-05-04 | 2023-05-10 | Pieris Pharmaceuticals GmbH | Proteins specific for cd137 |
| EP3292148B1 (en) | 2015-05-04 | 2024-01-24 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| SI3298030T1 (sl) | 2015-05-18 | 2023-05-31 | Pieris Pharmaceuticals Gmbh | Protirakav fuzijski polipeptid |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| MX2018000447A (es) | 2015-07-15 | 2018-08-15 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas especificas para lag-3. |
| EA035586B1 (ru) | 2015-11-30 | 2020-07-10 | Пиерис Острелиа Пти Лтд. | Новые антиангиогенные слитые белки |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| BR112019014691A2 (pt) | 2017-01-18 | 2020-04-07 | Pieris Pharmaceuticals Gmbh | muteínas de lipocalina com afinidade de ligação para lag-3 |
| RS64343B9 (sr) | 2018-07-31 | 2023-11-30 | Pieris Pharmaceuticals Gmbh | Novi fuzioni protein specifičan za cd137 i pd-l1 |
| MX2021010039A (es) | 2019-02-26 | 2021-09-21 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas de fusion especificas para cd137 y gpc3. |
| WO2021245240A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| BR112023020859A2 (pt) | 2021-04-08 | 2023-12-12 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina específicas para fator de crescimento do tecido conjuntivo (ctgf) |
| WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
| WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3719046A1 (de) * | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5238915A (en) * | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| ATE214940T1 (de) * | 1993-11-10 | 2002-04-15 | Enzon Inc | Verbesserte interferon-polymerkonjugate |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| ATE262920T1 (de) * | 1995-11-02 | 2004-04-15 | Schering Corp | Kontinuierliche, niedrigdosierte zytokine- infusionstherapie |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| KR20010052622A (ko) * | 1998-06-08 | 2001-06-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 |
-
1999
- 1999-05-29 KR KR1020007013843A patent/KR20010052622A/ko active Search and Examination
- 1999-05-29 JP JP2000553084A patent/JP3839667B2/ja not_active Expired - Lifetime
- 1999-05-29 BR BR9911076-8A patent/BR9911076A/pt not_active Application Discontinuation
- 1999-05-29 IL IL13978699A patent/IL139786A0/xx active IP Right Grant
- 1999-05-29 DK DK99927804T patent/DK1087778T3/da active
- 1999-05-29 NZ NZ508249A patent/NZ508249A/xx not_active IP Right Cessation
- 1999-05-29 CZ CZ20004487A patent/CZ298681B6/cs not_active IP Right Cessation
- 1999-05-29 DE DE69927971T patent/DE69927971T2/de not_active Expired - Lifetime
- 1999-05-29 ID IDW20002551A patent/ID29285A/id unknown
- 1999-05-29 RS YUP-770/00A patent/RS50144B/sr unknown
- 1999-05-29 AT AT99927804T patent/ATE307597T1/de active
- 1999-05-29 CA CA002334267A patent/CA2334267C/en not_active Expired - Lifetime
- 1999-05-29 PL PL344794A patent/PL192364B1/pl unknown
- 1999-05-29 WO PCT/EP1999/003746 patent/WO1999064016A1/en active IP Right Grant
- 1999-05-29 CN CNB998071706A patent/CN1170543C/zh not_active Expired - Lifetime
- 1999-05-29 TR TR2000/03635T patent/TR200003635T2/xx unknown
- 1999-05-29 EP EP99927804A patent/EP1087778B1/en not_active Expired - Lifetime
- 1999-05-29 RU RU2003119460/14A patent/RU2271217C2/ru active
- 1999-05-29 KR KR1020057009098A patent/KR20050055053A/ko not_active Application Discontinuation
- 1999-05-29 HU HU0102033A patent/HU228218B1/hu unknown
- 1999-05-29 SI SI9930843T patent/SI1087778T1/sl unknown
- 1999-05-29 ES ES99927804T patent/ES2251196T3/es not_active Expired - Lifetime
- 1999-05-29 AU AU45033/99A patent/AU767131B2/en not_active Expired
- 1999-06-02 SA SA99200208A patent/SA99200208B1/ar unknown
- 1999-06-04 AR ARP990102664A patent/AR019855A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035303A patent/CO5050297A1/es unknown
- 1999-06-04 PE PE1999000478A patent/PE20000560A1/es not_active Application Discontinuation
- 1999-06-04 TW TW088109246A patent/TWI241913B/zh not_active IP Right Cessation
- 1999-06-07 MY MYPI99002297A patent/MY124091A/en unknown
- 1999-06-08 MA MA25613A patent/MA26641A1/fr unknown
-
2000
- 2000-11-20 IL IL139786A patent/IL139786A/en not_active IP Right Cessation
- 2000-11-21 ZA ZA200006814A patent/ZA200006814B/en unknown
- 2000-11-24 HR HR20000808A patent/HRP20000808A2/hr not_active Application Discontinuation
- 2000-12-05 NO NO20006178A patent/NO325598B1/no not_active IP Right Cessation
-
2001
- 2001-11-07 US US10/037,064 patent/US20030053986A1/en not_active Abandoned
- 2001-12-20 HK HK01108946A patent/HK1037981A1/xx not_active IP Right Cessation
-
2004
- 2004-07-26 US US10/899,726 patent/US20050031589A1/en not_active Abandoned
-
2006
- 2006-02-02 JP JP2006025756A patent/JP2006160759A/ja active Pending
-
2007
- 2007-01-24 US US11/657,287 patent/US20070196385A1/en not_active Abandoned
-
2010
- 2010-08-04 CL CL2010000828A patent/CL2010000828A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325598B1 (no) | Anvendelse av PEG-IFN-<alfa>2A konjugat og ribavirin for fremstilling av et medikament for behandling av kronisk hepatitt C infeksjoner og PEG-IFN-<alfa>2A konjugater sammen med ribavirin for anvendelse i terapi. | |
| WO2001012214A2 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| US20080317714A1 (en) | Method of Treating Hepatitis B Viral Infection | |
| US20010046957A1 (en) | Method for treating hepatitis C | |
| AU746648B2 (en) | Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C | |
| MXPA00011665A (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c | |
| MXPA00002570A (en) | Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |